The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Bertino, Gaetano ^a   Demma, Shirin ^a   Ardiri, Annalisa ^a   Proiti, Maria ^a   Mangia, Alessandra ^b   Gruttadauria, Salvatore ^c   Toro, Adriana ^a   Di Carlo, Isidoro ^a   Malaguarnera, Giulia ^a   Bertino, Nicoletta ^a   Malaguarnera, Mariano ^a   Malaguarnera, Michele ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTIGEN 519; CANCER TESTIS ANTIGEN; GLYPICAN 3; MELANOMA ANTIGEN; NY ESO 1 ANTIGEN; SSX 2 ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; ANIMAL; CARCINOMA, HEPATOCELLULAR; IMMUNOLOGY; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES;

SCOPUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS;

EID: 84928116687     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/731469     Document Type: Review

References (119)

1. K. J. Lafaro, A. N. Demirjian, and T. M. Pawlik, "Epidemiology of hepatocellular carcinoma," Surgical Oncology Clinics of North America, vol. 24, no. 1, pp. 1-17, 2014.
2. C.-L. Lin and J.-H. Kao, "Risk stratification for hepatitis B virus related hepatocellular carcinoma," Journal of Gastroenterology and Hepatology, vol. 28, no. 1, pp. 10-17, 2013.
3. T. Umemura, T. Ichijo, K. Yoshizawa, E. Tanaka, and K. Kiyosawa, "Epidemiology of hepatocellular carcinoma in Japan," Journal of Gastroenterology, vol. 44, supplement, no. 19, pp. 102-107, 2009.
4. J. A. Davila, J. R. Kramer, Z. Duan et al., "Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors," Hepatology, vol. 57, no. 5, pp. 1858-1868, 2013.
5. G. Baffy, E. M. Brunt, and S. H. Caldwell, "Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace," Journal of Hepatology, vol. 56, no. 6, pp. 1384-1391, 2012.
6. G. Bertino, A. M. Ardiri, F. T. Al et al., "Obesity and related diseases: an epidemiologic study in eastern Sicily," Minerva Gastroenterologica e Dietologica, vol. 52, no. 4, pp. 379-385, 2006.
7. M. Malaguarnera, M. Vacante, C. Russo et al., "Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with interferon and ribavirin: rosuvastatin reducesNAFLD inHCVpatients,"HepatitisMonthly, vol. 11,no. 2, pp. 92-98, 2011.
8. J. M. Llovet, A. Burroughs, and J. Bruix, "Hepatocellular carcinoma," The Lancet, vol. 362, no. 9399, pp. 1907-1917, 2003.
9. A. Toro, A. Ardiri, M. Mannino et al., "Effect of pre-and posttreatment fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study," BMC Surgery, vol. 14, no. 1, p. 40, 2014.
10. I. Di Carlo, M. Mannino, A. Toro et al., "Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature," World Journal of Surgical Oncology, vol. 10, article 79, 2012.
11. G. Bertino, A. M. Ardiri, M. M. Santonocito, and P. M. Boemi, "Some patients with HCC haven't abnornormal des-gammacarboxy prothrombin and alpha-fetoprotein levels," Panminerva Medica, vol. 51, no. 2, pp. 133-134, 2009.
12. G. Bertino, A. Ardiri, M. Malaguarnera, G. Malaguarnera, N. Bertino, andG. S. Calvagno, "Hepatocellualar carcinoma serum markers," Seminars in Oncology, vol. 39,no. 4, pp. 410-433, 2012.
13. G. Bertino, S. Neri, C. M. Bruno et al., "Diagnostic and prognostic value of alpha-fetoprotein, des-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma," Minerva Medica, vol. 102, no. 5, pp. 363-371, 2011.
14. G. Bertino, A. M. Ardiri, G. S. Calvagno, N. Bertino, and P. M. Boemi, "Prognostic and diagnostic value of des-carboxy prothrombin in liver cancer," Drug News and Perspectives, vol. 23, no. 8, pp. 498-508, 2010.
15. G. Bertino, A. M. Ardiri, P. M. Boemi et al., "A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma," Panminerva Medica, vol. 50, no. 3, pp. 221-226, 2008.
16. A. Biondi, G. Malaguarnera, M. Vacante et al., "Elevated serum levels of Chromogranin A in hepatocellular carcinoma," BMC Surgery, vol. 12, article 7, supplement 1, 2012.
17. G. Malaguarnera, I. Paladina, M. Giordano, M. Malaguarnera, G. Bertino, and M. Berretta, "Serum markers of intrahepatic cholangiocarcinoma," Disease Markers, vol. 34, no. 4, pp. 219-228, 2013.
18. G. Bertino, A. Ardiri, S. Demma et al., "Rare benign tumors of the liver: still rare" Journal of Gastrointestinal Cancer, vol. 45, no. 2, pp. 202-217, 2014.
19. A. Toro, A. E. Mahfouz, A. Ardiri et al., "What is changing in indications and treatment of hepatic hemangiomas. A review," Annals of Hepatology, vol. 13, no. 4, pp. 327-339, 2014.
20. G. Bertino, A. M. Ardiri, G. S. Calvagno et al., "Carbohydrate 19. 9 antigen serum levels in liver disease," BioMed Research International, vol. 2013,Article ID 531640, 6 pages, 2013.
21. T. F. Greten, M. P. Manns, and F. Korangy, "Immunotherapy of hepatocellular carcinoma," Journal of Hepatology, vol. 45, no. 6, pp. 868-878, 2006.
22. T. F. Greten, M. P. Manns, and F. Korangy, "Immunotherapy of HCC," Reviews on Recent Clinical Trials, vol. 3, no. 1, pp. 31-39, 2008.
23. E. Unitt, A. Marshall, W. Gelson et al., "Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation," Journal of Hepatology, vol. 45, no. 2, pp. 246-253, 2006.
24. T. Takayama, T. Sekine, M. Makuuchi et al., "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial," The Lancet, vol. 356, no. 9232, pp. 802-807, 2000.
25. K. Ohnishi, H. Yoshioka, S. Ito, and K. Fujiwara, "Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma," Hepatology, vol. 27, no. 1, pp. 67-72, 1998.
26. S. Shiina, K. Tagawa, T. Unuma et al., "Percutaneous ethanol injection therapy for hepatocellular carcinoma: a histopathologic study," Cancer, vol. 68, no. 7, pp. 1524-1530, 1991.
27. R. Thimme, M. Neagu, T. Boettler et al., "Comprehensive analysis of the fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma," Hepatology, vol. 48,no. 6, pp. 1821-1833, 2008.
28. H. Komori, T. Nakatsura, S. Senju et al., "Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma," Clinical Cancer Research, vol. 12, no. 9, pp. 2689-2697, 2006.
29. X.-Y. Shang, H.-S. Chen, H.-G. Zhang et al., "The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients," Clinical Cancer Research, vol. 10, no. 20, pp. 6946-6955, 2004.
30. G. Bricard, H. Bouzourene, O. Martinet et al., "Naturally acquiredMAGE-A10-and SSX-2-specificCD8+ Tcell responses in patients with hepatocellular carcinoma," The Journal of Immunology, vol. 174, no. 3, pp. 1709-1716, 2005.
31. E. Mizukoshi, Y. Nakamoto, Y. Marukawa et al., "Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma," Hepatology, vol. 43,no. 6, pp. 1284-1294, 2006.
32. A. M. Aref, N. T. Hoa, L. Ge et al., "HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma," Journal ofOncoTargets andTherapy, vol. 7, pp. 1061-1070, 2014.
33. L. H. Butterfield, A. Ribas, W. S. Meng et al., "Tcell responses to HLA-A0201 immunodominant peptides derived from alphafetoprotein in patients with hepatocellular cancer," Clinical Cancer Research, vol. 9, no. 16, part 1, pp. 5902-5908, 2003.
34. H. Komori, T. Nakatsura, S. Senju et al., "Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma," Clinical Cancer Research, vol. 12, no. 9, pp. 2689-2697, 2006.
35. H. Xu, N. Gu, Z.-B. Liu et al., "NY-ESO-1 expression in hepatocellular carcinoma: a potential new marker for early recurrence after surgery," Oncology Letters, vol. 3, no. 1, pp. 39-44, 2012.
36. F. Korangy, L. A. Ormandy, J. S. Bleck et al., "Spontaneous tumor-specific humoral and cellular immune responses to NYESO-1 in hepatocellular carcinoma," Clinical Cancer Research, vol. 10, no. 13, pp. 4332-4341, 2004.
37. G. Bricard, H. Bouzourene, O. Martinet et al., "Naturally acquiredMAGE-A10-and SSX-2-specificCD8+ Tcell responses in patients with hepatocellular carcinoma," The Journal of Immunology, vol. 174, no. 3, pp. 1709-1716, 2005.
38. J. Liang, T. Ding, Z.-W. Guo et al., "Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression," British Journal of Cancer, vol. 109, no. 4, pp. 1031-1039, 2013.
39. A. Zerbini, M. Pilli, P. Soliani et al., "Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma," Journal of Hepatology, vol. 40, no. 1, pp. 102-109, 2004.
40. L. Carulli and C. Anzivino, "Telomere and telomerase in chronic liver disease and hepatocarcinoma," World Journal of Gastroenterology, vol. 20, no. 20, pp. 6287-6292, 2014.
41. A. W. Bird and A. A. Hyman, "Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A," The Journal of Cell Biology, vol. 182, no. 2, pp. 289-300, 2008.
42. S. L. Warner, B. J. Stephens, S. Nwokenkwo et al., "Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells," Clinical Cancer Research, vol. 15, no. 21, pp. 6519-6528, 2009.
43. Y. Ma, D. Lin, W. Sun et al., "Expression of targeting protein for Xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer," Clinical Cancer Research, vol. 12, no. 4, pp. 1121-1127, 2006.
44. S. Tanaka, S. Arii, M. Yasen et al., "Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy," British Journal of Surgery, vol. 95, no. 5, pp. 611-619, 2008.
45. C. W. Yang, J. Y. Su, A. P. Tsou et al., "Integrative genomics based identification of potential human hepatocarcinogenesisassociated cell cycle regulators: RHAMM as an example," Biochemical and Biophysical Research Communications, vol. 330, no. 2, pp. 489-497, 2005.
46. R. Satow, M. Shitashige, Y. Kanai et al., "Combined functional genome survey of therapeutic targets for hepatocellular carcinoma," Clinical Cancer Research, vol. 16, no. 9, pp. 2518-2528, 2010.
47. M. A. Burchill, J. Yang, K. B. Vang, and M. A. Farrar, "Interleukin-2 receptor signaling in regulatory T cell development and homeostasis," Immunology Letters, vol. 114, no. 1, pp. 1-8, 2007.
48. A. M. Thornton and E. M. Shevach, "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production,"The Journal of Experimental Medicine, vol. 188, no. 2, pp. 287-296, 1998.
49. C. A. Piccirillo and E. M. Shevach, "Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells," The Journal of Immunology, vol. 167, no. 3, pp. 1137-1140, 2001.
50. R. S. Bystry, V. Aluvihare, K. A. Welch, M. Kallikourdis, and A. G. Betz, "B cells and professional APCs recruit regulatory T cells via CCL4,"Nature Immunology, vol. 2, no. 12, pp. 1126-1132, 2001.
51. S. Onizuka, I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama, "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor ) monoclonal antibody," Cancer Research, vol. 59, no. 13, pp. 3128-3133, 1999.
52. A. Gallimore and S. Sakaguchi, "Regulation of tumour immunity by CD25+ Tcells," Immunology, vol. 107, no. 1,pp. 5-9, 2002.
53. E. M. Aandahl, J. Michäelsson, W. J. Moretto, F. M. Hecht, and D. F. Nixon, "Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens," Journal of Virology, vol. 78, no. 5, pp. 2454-2459, 2004.
54. E. Unitt, S. M. Rushbrook, A. Marshall et al., "Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of Tregulatory cells," Hepatology, vol. 41, no. 4, pp. 722-730, 2005.
55. H. Wu, P. Chen, R. Liao et al., "Intratumoral regulatory T cells with higher prevalence and more suppressive activity in hepatocellular carcinoma patients," Journal of Gastroenterology and Hepatology, vol. 28, no. 9, pp. 1555-1564, 2013.
56. H. Q. Zhao, W. M. Li, Z. Q. Lu, and Y. M. Yao, "Roles of tregs in development of hepatocellular carcinoma: a meta-analysis," World Journal ofGastroenterology, vol. 20,no. 24,pp. 7971-7978, 2014.
57. C. Miroux, T. Vausselin, and N. Delhem, "Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response," Expert Opinion on Biological Therapy, vol. 10, no. 11, pp. 1563-1572, 2010.
58. J. Schrader, "Therole of MDSCs in hepatocellular carcinoma: in vivo veritas?" Journal of Hepatology, vol. 59, no. 5, pp. 921-923, 2013.
59. C.-E. Hu, J. Gan, R.-D. Zhang, Y.-R. Cheng, and G.-J. Huang, "Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function," Scandinavian Journal of Gastroenterology, vol. 46, no. 2, pp. 156-164, 2011.
60. P. Sinha, V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg, "Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response," The Journal of Immunology, vol. 179, no. 2, pp. 977-983, 2007.
61. D. Ilkovitch and D. M. Lopez, "The liver is a site for tumorinduced myeloid-derived suppressor cell accumulation and immunosuppression," Cancer Research, vol. 69, no. 13, pp. 5514-5521, 2009.
62. D. Gabrilovich, "Mechanisms and functional significance of tumour-induced dendritic-cell defects," Nature Reviews Immunology, vol. 4, no. 12, pp. 941-952, 2004.
63. B. Hoechst, T. Voigtlaender, L. Ormandy et al., "Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKP30 receptor," Hepatology, vol. 50, no. 3, pp. 799-807, 2009.
64. B. Hoechst, L. A. Ormandy, M. Ballmaier et al., "A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells," Gastroenterology, vol. 135, no. 1, pp. 234-243, 2008.
65. B. Hoechst, T. Voigtlaender, L. Ormandy et al., "Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor," Hepatology, vol. 50, no. 3, pp. 799-807, 2009.
66. F. Arihara, E. Mizukoshi, M. Kitahara et al., "Increase in CD14+HLA-DR/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis," Cancer Immunology, Immunotherapy, vol. 62, no. 8, pp. 1421-1430, 2013.
67. T. F. Greten, L. A. Ormandy, A. Fikuart et al., "Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC," Journal of Immunotherapy, vol. 33, no. 2, pp. 211-218, 2010.
68. Y. Han, Z. Chen, Y. Yang et al., "Human CD14+CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma," Hepatology, vol. 59, no. 2, pp. 567-579, 2014.
69. T. Hato, L. Goyal, T. F. Greten, D. G. Duda, and A. X. Zhu, "Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions," Hepatology, vol. 60, no. 5, pp. 1776-1782, 2014.
70. B. Hoechst, L. A. Ormandy, M. Ballmaier et al., "A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T Cells," Gastroenterology, vol. 135, no. 1, pp. 234-243, 2008.
71. K. Fujiwara, T. Higashi, K. Nouso et al., "Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma," Journal of Gastroenterology and Hepatology, vol. 19, no. 10, pp. 1121-1127, 2004.
72. K. Kurokohchi, M. Carrington, D. L. Mann et al., "Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma," Hepatology, vol. 23, no. 5, pp. 1181-1188, 1996.
73. T. Tatsumi, T. Takehara, K. Katayama et al., "Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma," Hepatology, vol. 25,no. 5, pp. 1108-1114, 1997.
74. F. Shi, M. Shi, Z. Zeng et al., "PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients," International Journal of Cancer, vol. 128, no. 4, pp. 887-896, 2011.
75. S. Chen, L.-F. Lee, T. S. Fisher et al., "Combination of 4-1BB agonist and PD-1 antagonist promotes anti-tumor effector/memory CD8 T cells in a poorly immunogenic tumor model," Cancer Immunology Research, 2014.
76. R. S. Herbst, J. C. Soria, M. Kowanetz et al., "Predictive correlates of response to the anti-PD-L1 antibodyMPDL3280A in cancer patients," Nature, vol. 515, no. 7528, pp. 563-567, 2014.
77. B. S. Henick, R. S. Herbst, and S. B. Goldberg, "The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer," Expert Opinion onTherapeutic Targets, vol. 18, no. 12, pp. 1407-1420, 2014.
78. D. Petrovic, Z. Stamataki, E. Dempsey et al., "Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion," Hepatology, vol. 53,no. 6, pp. 1846-1853, 2011.
79. J. M. O'Bryan, J. A. Potts, H. L. Bonkovsky, A. Mathew, and A. L. Rothman, "Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes," PLoS ONE, vol. 6, no. 8,Article ID e20922, 2011.
80. A. D. Pardee and L. H. Butterfield, "Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities," OncoImmunology, vol. 1, no. 1, pp. 48-55, 2012.
81. T. Stroffolini, A. Spadaro, V. Di Marco et al., "Current practice of chronic hepatitis B treatment in Southern Italy," European Journal of Internal Medicine, vol. 23, no. 5, pp. e124-e127, 2012.
82. G. Bertino, A. Ardiri, P. M. Boemi et al., "Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis," European Journal of Clinical Pharmacology, vol. 66, no. 10, pp. 1055-1063, 2010.
83. G. Malaguarnera, M. Pennisi, C. Gagliano et al., "Acetyl-Lcarnitine supplementation during HCV therapy with pegylated interferon- 2b plus ribavirin: effect on work performance; a randomized clinical trial," Hepatitis Monthly, vol. 14, no. 5, Article ID e11608, 2014.
84. M. Malaguarnera, M. Vacante, M. Giordano et al., "L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with peg interferon- 2b plus ribavirin," World Journal of Gastroenterology, vol. 17, no. 39, pp. 4414-4420, 2011.
85. M. Malaguarnera, M. Vacante, G. Bertino et al., "The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon- 2b plus ribavirin," Journal of Interferon and Cytokine Research, vol. 31, no. 9, pp. 653-659, 2011.
86. C. M. Bruno, M. Valenti, G. Bertino et al., "Relationship between circulating interleukin-10 and histological features in patients with chronicChepatitis,"Annals of SaudiMedicine, vol. 31, no. 4, pp. 360-364, 2011.
87. F. Zhao, F. Korangy, and T. F. Greten, "Cellular immune suppressormechanisms inpatientswithhepatocellular carcinoma," Digestive Diseases, vol. 30, no. 5, pp. 477-482, 2012.
88. L. Cai, Z. Zhang, L. Zhou et al., "Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients," Clinical Immunology, vol. 129, no. 3, pp. 428-437, 2008.
89. M. ElAnsary, S. Mogawer, S. A. Elhamidet al., "Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC," Journal of Cancer Research and Clinical Oncology, vol. 139, no. 1, pp. 39-48, 2013.
90. F. Zhao, F. Korangy, and T. F. Greten, "Cellular immune suppressormechanisms inpatientswithhepatocellular carcinoma," Digestive Diseases, vol. 30, no. 5, pp. 477-482, 2012.
91. J.-H. Zhong, L. Ma, L.-C. Wu et al., "Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review," International Journal of Clinical Practice, vol. 66, no. 1, pp. 21-27, 2012.
92. W. C. Lee, H. C. Wang, C. F. Hung, P. F. Huang, C. R. Lia, and M. F. Chen, "Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial," Journal of Immunotherapy, vol. 28, no. 5, pp. 496-504, 2005.
93. E. Mizukoshi, Y. Nakamoto, K. Arai et al., "Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma," Hepatology, vol. 53, no. 4, pp. 1206-1216, 2011.
94. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastatic melanoma," The New England Journal of Medicine, vol. 363, no. 8, pp. 711-723, 2010.
95. C. Robert, L. Thomas, I. Bondarenko et al., "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma," The New England Journal ofMedicine, vol. 364, no. 26, pp. 2517-2526, 2011.
96. L. Calabrò, A. Morra, E. Fonsatti et al., "Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial," The Lancet Oncology, vol. 14, no. 11, pp. 1104-1111, 2013.
97. B. Sangro, C. Gomez-Martin, M. de la Mata et al., "A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C," Journal of Hepatology, vol. 59, no. 1, pp. 81-88, 2013.
98. J. F. Grosso andM. N. Jure-Kunkel, "CTLA-4 blockade in tumor models: an overview of preclinical and translational research," Cancer immunity, vol. 13, pp. 5-19, 2013.
99. K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson, "Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity," The Journal of Experimental Medicine, vol. 207, no. 10, pp. 2187-2194, 2010.
100. O. Hamid, C. Robert, A. Daud et al., "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma," The New England Journal of Medicine, vol. 369, no. 2, pp. 134-144, 2013.
101. J. D. Wolchok,H. Kluger,M. K. Callahan et al., "Nivolumab plus Ipilimumab in advanced melanoma,"The New England Journal of Medicine, vol. 369, no. 2, pp. 122-133, 2013.
102. R. Berger, R. Rotem-Yehudar, G. Slama et al., "Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies," Clinical Cancer Research, vol. 14, no. 10, pp. 3044-3051, 2008.
103. A. D. Pardee, D. McCurry, S. Alber, P. Hu, A. L. Epstein, and W. J. Storkus, "A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment," Cancer Research, vol. 70, no. 22, pp. 9041-9052, 2010.
104. J. M. Llovet, S. Ricci, V. Mazzaferro et al., "Sorafenib in advanced hepatocellular carcinoma," The New England Journal of Medicine, vol. 359, no. 4, pp. 378-390, 2008.
105. B. Xie, D. H. Wang, and S. J. Spechler, "Sorafenib for treatment of hepatocellular carcinoma: a systematic review," Digestive Diseases and Sciences, vol. 57, no. 5, pp. 1122-1129, 2012.
106. A. X. Zhu, D. G. Duda, D. V. Sahani, and R. K. Jain, "HCC and angiogenesis: Possible targets and future directions," Nature Reviews Clinical Oncology, vol. 8, no. 5, pp. 292-301, 2011.
107. J. Heo, T. Reid, L. Ruo et al., "Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer," Nature Medicine, vol. 19, no. 3, pp. 329-336, 2013.
108. L. Liu, W. Wang, H. Chen et al., "EASL-and mRECISTevaluated responses to combination therapy predict survival in patients with hepatocellular carcinoma," Clinical Cancer Research, vol. 20, no. 6, pp. 1623-1631, 2014.
109. F. Y. Yao, "Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment?" Liver Transplantation, vol. 20, no. 3, pp. 257-260, 2014.
110. N. Mehta, J. L. Dodge, J. P. Roberts, R. Hirose, and F. Y. Yao, "Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list," Liver Transplantation, vol. 20, no. 5, pp. 627-628, 2014.
111. J. M. Llovet and J. Bruix, "Molecular targeted therapies in hepatocellular carcinoma," Hepatology, vol. 48, no. 4, pp. 1312-1327, 2008.
112. M. Y. Ali, C. F. Grimm, M. Ritter et al., "Activation of dendritic cells by local ablation of hepatocellular carcinoma," Journal of Hepatology, vol. 43, no. 5, pp. 817-822, 2005.
113. R. L. Bogorad, H. Yin, A. Zeigerer et al., "Nanoparticleformulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice," Nature Communications, vol. 5, article 3869, 2014.
114. X. H. Huang, W. H. Jian, Z. F. Wu et al., "Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation," Oncotarget, vol. 5, no. 14, pp. 5570-5580, 2014.
115. G. K. Abou-Alfa, "Sorafenib use in hepatocellular carcinoma: more questions than answers," Hepatology, vol. 60, no. 1, pp. 15-18, 2014.
116. T. Arizumi, K. Ueshima, H. Takeda et al., "Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma," Journal of Gastroenterology, vol. 49, no. 12, pp. 1578-1587, 2014.
117. G. Bertino, I. Di Carlo, A. Ardiri et al., "Systemic therapies in hepatocellular carcinoma: present and future," Future Oncology, vol. 9, no. 10, pp. 1533-1548, 2013.
118. G. Bertino, S. Demma, N. Bertino, and A. Ardiri, "Management of hepatocellular carcinoma: an update at the start of 2014," Journal of Gastrointestinal & Digestive System, vol. 4, no. 2, pp. 1-7, 2014.
119. G. Bertino, S. Demma, A. Ardiri et al., "Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies," BioMed Research International, vol. 2014, Article ID 203693, 15 pages, 2014.